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Identiﬁcation and characterization of local molecules directing the differentiation of chondrocytes
to either transient or permanent cartilage are major issues in cartilage biology. Here, we found CCN
family protein 3 (CCN3) was abundantly produced in rat developing epiphyseal cartilage. Evalua-
tions in vitro showed that CCN3 repressed epiphyseal chondrocyte proliferation, while promoting
matrix production in multiple assays performed. Furthermore, CCN3 enhanced the articular chondr-
ocytic phenotype; whereas it repressed the one representing endochondral ossiﬁcation. Addition-
ally, the phenotype of growth plate chondrocytes and chondrogenic progenitors also appeared to
be affected by CCN3 in a similar manner. These ﬁndings suggest a signiﬁcant role of CCN3 in induc-
ing chondrocytes to articular ones during joint formation.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cartilage is a unique tissue that has been attracting the atten-
tion of a number of researchers, because of the involvement of
the broad spectrum of biological issues that remain unresolved.
The chondrocytes involved in cartilage can be classiﬁed into two
groups forming transient and permanent cartilages. The former
type of chondrocyte passes through the highly complex and orga-
nized differentiation steps leading to physiological endochondral
ossiﬁcation [1]; whereas in permanent cartilage, ossiﬁcation is pre-
vented by unknown molecules and signaling pathways. In the
same way, the molecules and pathways responsible for bringing
about pathological cartilage ossiﬁcation, as observed in osteoar-
thritis, are also yet to be clariﬁed. In this context, a particularly
interesting issue is the mechanism of articular cartilage develop-
ment within synovial joints. Articular cartilage is a thin strip of
cartilage persisting throughout the entire ossiﬁcation process as
a part of the whole cartilaginous template that maintains its phe-
notype for decades [1]. Although some researchers have alreadychemical Societies. Published by E
Biochemistry and Molecular
edicine, Dentistry and Phar-
yama 700-8525, Japan. Fax:
S. Kubota), takigawa@md.o-shed some light on the origin of the articular chondrocytes [2],
the molecules acting locally as well as the pathways responsible
for dividing the epiphyseal chondrocytes into two populations in
the epiphysis have not yet been identiﬁed nor their actions fully
understood.
The CCN family of regulatory factors [3–7] has been shown to
have great inﬂuence on chondrocyte biology and cartilage homeo-
stasis. CCN is an acronym that stands for Cyr61 (cysteine-rich 61),
CTGF (connective tissue growth factor) and NOV (nephroblastoma
overexpressed), the three founder members of this family [3,7]. All
of the proteins in this family share a tetramodular structure, except
for the trimodular member CCN5, and participate in a variety of
cellular events such as migration, adhesion, proliferation, differen-
tiation, and neoplastic transformation [3]. CCN2/connective tissue
growth factor (CTGF) seems to be especially important for cartilage
metabolism [7,8]. It has been demonstrated by our group that
CCN2 is a potent promoter of both proliferation of and extracellular
matrix synthesis by growth plate [9], articular [9], and auricular
[10] chondrocytes. Interestingly, Ccn2 knockout mice have their
endochondral ossiﬁcation process compromised [11,12], display-
ing a greatly decreased ability for matrix calciﬁcation, which was
accompanied by increased expression of CCN3 [11]. It should be
also noted that costal chondrocytes from wild-type mice are inhib-
ited in their proliferation and display no matrix calciﬁcation, when
treated in culture with exogenous human recombinant CCN3
(rCCN3) [11].lsevier B.V. All rights reserved.
Table 1
List of the speciﬁc real-time RT-PCR primer pairs used for the respective genes and
species.
Gene name Direction Nucleotide sequence
Rat/mouse CCN3 Sense 50-CCTGGACCTCATCAGCATTT-30
Anti-sense 50-TCAAGGGCCAGCAGTTCA-30
Rat aggrecan Sense 50-CTTGGGCAGAAGAAAGATCG-30
Anti-sense 50-GTGCTTGTAGGTGTTGGGGT-30
Mouse aggrecan Sense 50-GAGGAGAGAACTGGAGAAG-30
Anti-sense 50-GGCGATAGTGGAATACAAC-30
Rat/mouse tenascin-C Sense 50-ACCAACTGTGCCCTGTCCTA-30
Anti-sense 50-ATTTCGGAAGTTGCTGGGTC-30
Rat type X collagen Sense 50-CCCAGGGTTACCAGGACCAA-30
Anti-sense 50-GTTCACCTCTTGGACCTGCC-30
Mouse type X
collagen
Sense 50-CCCAGGGTTACCAGGACAAA-30
Anti-sense 50-GTTCACCTCTTGGACCTGCG-30
Rat/mouse rS18 Sense 50-GCGAATTCCTGCCAGTAGCATATGCTG-30
Anti-sense 50-GGAAGCTTAGAGGAGCAGCGACCAAAGC-30
Rat/mouse GAPDH Sense 50-GCCAAAAGGGTCATCATCTC-30
Anti-sense 50-GTCTTCTGGGTGGCAGTGAT-30
3034 D. Janune et al. / FEBS Letters 585 (2011) 3033–3040One of the distinct characteristics of articular chondrocytes
in vivo is less proliferative activity than that of growth-plate
chondrocytes, which are forced to proliferate. Therefore, we
hypothesized that CCN3 might be one of the factors involved in
driving the articular chondrocyte phenotype, acting by slowing
down their proliferation and henceforth setting them apart from
the chondrocytes involved in endochondral ossiﬁcation. In the
present study, after verifying the production of CCN3 in vivo, we
evaluated the effect of exogenous CCN3 mainly on the cells from
the distal femoral epiphysis of rats before secondary ossiﬁcation.
The ﬁndings we obtained indicate novel roles of CCN3 in directing
the differentiation as well as proliferation of these chondrocytes.
2. Materials and methods
2.1. Immunohistochemistry (IHC), immunocytochemistry (ICC) and
Western blotting analysis
All of the animal experiments were conducted according to the
Guidelines for Animal Research, and were approved by the Animal
Committee of Okayama University. For IHC, femurs from 5-day-old
Sprague–Dawley rats were ﬁxed in 10% formalin, decalciﬁed, and
prepared for cryosectioning as described elsewhere [13]. Non-spe-
ciﬁc antigens were blocked with 10% bovine serum albumin (BSA)
for 30 min. Sectionswere exposed overnight at 4 C to a rabbit poly-
clonal antibody against CCN3 (ab10888: Abcam, Cambridge, UK) at
a dilution of 1:50 and subsequently incubated with ﬂuorescein-
conjugated secondary antibody (1:100) for 1 h at room tempera-
ture. The slides were mounted with Prolong Gold containing
anti-fading reagent and DAPI (Invitrogen, Carlsbad, CA, USA).
For ICC, cells were cultivated for 3 days in 48-well plates. After
replacement of the medium with fresh medium, monensin (Bioleg-
end, San Diego, CA, USA), a drug that stops cellular secretion, was
added to the cultures at 1:1000. After 3 h, the cells were ﬁxed with
10% formalin and were blocked with 1% BSA for 30 min. Cells were
exposed for 1 h and a half at room temperature to the following
antibodies in blocking solution: the same ab10888 antibody against
CCN3 as used for IHC, diluted at 1:50; mouse monoclonal antibody
against aggrecan core protein (MAB1220: RD Systems,Minneapolis,
MN, USA), diluted at 1:50; and mouse monoclonal antibody against
tenascin-C (4C8MS: Novus Biologicals, Littleton, CO, USA), diluted
at 1:20. The negative control was prepared by omitting the primary
antibody. Thereafter, cells were exposed for 1 h, also at room tem-
perature, to ﬂuorescein-conjugated secondary antibody. Nuclei
were counterstained with DAPI. The number of cells positive for
each analyzed proteinwas determinedwith a Cellomics ArrayScan
VTI™ HCS Reader (Thermo Fisher Scientiﬁc, Waltham, MA, USA).
ForWesternblotting analysis, thedistal halves of the femoral dis-
tal epiphyseswere collected,minced andhadprotein extractedwith
a lysis buffer under sonication. After SDS–PAGE andWestern trans-
fer to PVDFmembrane, blocking was carried out with 5% skimmilk.
Detection was made with the same primary antibody against CCN3
used for IHCandsecondary antibodyagainst rabbit immunoglobulin
conjugated with horseradish peroxidase (HRP). Another primary
(Sigma, clone ac-47, produced in mouse) and HRP-conjugated
secondary antibodies were employed for the detection of b-actin.
Signals were developed and detected as described previously [15].
2.2. Isolation and culture of primary chondrocytes
Five-day-old Sprague–Dawley rats were euthanized with pen-
tobarbital. Epiphyseal cells were obtained from the distal third of
their femoral distal epiphysis, which was minced into small frag-
ments and digested with 0.15% (w/v) collagenase (Wako Pure
Chemicals, Osaka, Japan) in serum-free a-MEM (ICN BiomedicalsInc., Eschwege, Germany) at 37 C. Costal cartilage cells were
obtained from the ribcage area from the end of the ossiﬁed region
up to approximately 5 mm in the ventral direction. Cells were iso-
lated according to a procedure described elsewhere [14] with some
modiﬁcations. After enzymatic digestion, cells were ﬁltered
through a 100-lm nylon mesh (BD Falcon, Franklin Lakes, NJ,
USA) and then seeded at 104 cells/cm2 on cell culture plates coated
with collagen type I (Nitta, Osaka, Japan). Cells were cultured with
a-MEM medium supplemented with 10% fetal bovine serum (Can-
cera International, Rexclale, ON, Canada) at 37 C in a humidiﬁed
incubator with 5% CO2 atmosphere. Unless stated otherwise, the
medium was replaced every 3 days.
2.3. Assay for proteoglycan synthesis
Cells seeded in 48-well plates were grown to conﬂuence.
Twenty-four hours after the medium replacement, the cells were
treated with one of the following proteins: 2 nM or 0.5 nM human
recombinant CCN3, which was around the optimal dose of CCN3
shown previously for chondrocytes [11], with a glutathione
S-transferase (GST) tag at its N-terminus (GST-NOV; Abnova, Taipei,
Taiwan) or GST protein (Abnova; as a control). These proteins were
produced and puriﬁed from endotoxin-free wheat germ extract
in vitro. Five hours after the addition of the protein, all the wells re-
ceived [35S] sulfate to a ﬁnal concentration of 370 kBq/ml, and the
cultures were continued for a further 17 h. [35S] sulfate incorpora-
tion into glycosaminoglycans was determined as described [9].
2.4. DNA synthesis assay
Cells in 48-well plates were grown to sub-conﬂuence, and the
medium was refreshed once. Twenty-four hours after this medium
replacement, the cells were treated with 2 nM GST-CCN3 or GST
protein only (control). Twenty-four hours later, all wells received
[3H] thymidine at a ﬁnal concentration of 350 kBq/ml; and incuba-
tion was then continued for 4 h. The radioactivity of acid-precipita-
ble materials in the cells was counted in Clear-Sol (Nacalai Tesque,
Kyoto, Japan) scintillation cocktail [9].
2.5. Assay for matrix maturation
Cells were grown to conﬂuence in a 24-well plate. After
reaching conﬂuence, the cells were incubated in culture medium
Fig. 1. Distribution of CCN3 protein in rat developing epiphyseal cartilage. Serial sections were stained (left panels) or not (right panels) with anti-CCN3 serum. The cell nuclei
were visualized by DAPI. (A) 10magniﬁcation of the femoral distal epiphyseal pole of a 5-day-old rat. CCN3 protein is observed throughout the epiphyseal cartilage pole. (B)
20magniﬁcation of the upper white square in ‘‘A’’. (C) 20magniﬁcation of the lower white square in ‘‘A’’. Bars: 250 lm. (D) Western blotting analysis of the tissue extract
of the epiphyseal pole. Speciﬁc signals detected by the antibodies raised against the indicated proteins are pointed by arrowheads.
D. Janune et al. / FEBS Letters 585 (2011) 3033–3040 3035supplemented with either 2 nM or 0.5 nM GST-CCN3 or GST
(control group). Two weeks later, cells were ﬁxed and the amount
of proteoglycan accumulated was evaluated as described [11].
2.6. Cell metabolism assay
Viable cell numbers were estimated based on water-soluble tet-
razolium salt (WST)-1 reduction by mitochondrial dehydrogenase.
Following the medium replacement at sub-conﬂuence, the cells in
a 48-well plate were kept for 24 h; then 2 nM GST-CCN3 or GST
protein was added. Incubation was continued for a further 3 days,
after which TetraColor ONE (WST-1; Seikagaku, Japan) was added
to the medium. Twenty-two hours later, absorbances at 420 and
630 nm (for reference) were measured.2.7. Matrix mineralization assay
Cells were seeded in a 24-well plate and grown to conﬂuence.
Thereafter, the medium was replaced by that supplemented with
ascorbic acid (50 lg/ml) and b-glycerophosphate (2 mM). After
2 weeks, the cells were ﬁxed and matrix mineralization assay
was carried out as described [11].
2.8. Short hairpin RNA (shRNA) mediated CCN3 knockdown
The following oligonucleotides encoding the short hairpin RNA
against CCN3, 50-GATCCGCAAGAGCCTGGGGAAGCAATTCAAGA-
GATTGCTTCCCCAGGCTCTTGTTTTTTACGCGTG-30 (sense) and 50-
AATTCACGCGTAAAAAACAAGAGCCTGGGGAAGCAATCTCTTGAATTGCT
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Fig. 2. Effect of rCCN3 on the proteoglycan production by epiphyseal chondrocytes. (A) Total proteoglycan synthesis upon rCCN3 treatment at the indicated concentration
estimated in terms of radiolabeled sulfate incorporation. (B) Proteoglycan accumulation in culture over 2 weeks under rCCN3 treatment at the indicated concentrations, as
estimated from the optical absorbance of the alcian blue-stained proteoglycans. Data are presented as relative percentages versus each control (GST). ⁄P = 0.0002, ⁄⁄P = 0.002,
⁄⁄⁄P = 0.007, as indicated by the brackets.
3036 D. Janune et al. / FEBS Letters 585 (2011) 3033–3040TCCCCAGGCTCTTGCG-30 (antisense), were annealed and ligated into
the BamHI and EcoRI sites in the retroviral RNAi-Ready pSIREN-
RetroQ-ZsGreen vector (Takara Bio/Clontech, Otsu, Japan). A
control plasmid was made in the same way, but with the scram-
bled mature small interfering RNA sequence (shown in italic
cases). Thereafter, plasmids were transfected into Ecotropic Phoe-
nix (http://www.stanford.edu/group/nolan/retroviral_systems/
phx.html) packaging cells, and the viral supernatant was collected
and used to infect the murine prechondrocytic ATDC5 cell line [16].
Upon conﬂuence, the retrovirally transduced cells were treated
with insulin-transferrin-sodium selenite (ITS) for 3 days to induce
chondrocytic differentiation, as described previously [16]. Thereaf-
ter, total RNA was collected for subsequent analysis.
2.9. Reverse transcription and real-time PCR analysis
For the real-time PCR analysis, cells were grown in 6-well or 12-
well plates. Total RNA was extracted after epiphyseal chondrocytes
had been treated for 48 h with one of the following proteins; 2 nM
or 0.5 nM GST-CCN3 or GST, or after conﬂuent ATDC5 cells had
been incubated for 3 days. Total RNA extraction and reverse tran-
scription were performed as described [11]. Real-time PCR was
carried out with the cDNA templates obtained from the reverse
transcription by using the speciﬁc primers listed in Table 1. Theconditions and reagents used for the real-time PCR reaction were
the same as those described [15].
2.10. Statistical analysis
All the experiments were repeated at least twice and yielded
similar results. Data were analyzed by applying the unpaired Stu-
dent’s t-test.3. Results
3.1. In vivo distribution of CCN3 in the developing bone epiphysis
First, production and distribution of CCN3 was investigated
in vivo by examining the developing epiphyseal cartilages of 5-
day-old rats. CCN3 was found throughout the cartilage template
of the distal epiphyseal pole (Fig. 1A). At a higher magniﬁcation
(Fig. 1B and C), CCN3 was observed dominantly localized in the
chondrocyte territorial matrix, rather than in the interterritorial
matrix. Such a ﬁnding is congruent with the matricellular molecu-
lar property of CCN family proteins [6]. It should be noted that sig-
niﬁcant signals were also present associated with the cells. To
conﬁrm these observations, we biochemically analyzed the CCN3
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rCCN3 estimated by performing the WST-1 assay. Data are presented as relative
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Fig. 4. Phenotypical comparison of primary rat epiphyseal and costal chondrocytes.
(A) Difference in the percentage of tenascin-C positive cells between the popula-
tions from different origins, as illustrated by the pie graphs. (B) Matrix calciﬁcation
ability of the cells of both origin was estimated by determining the intensity of the
alizarin red staining. Chondrocytes of epiphyseal origin showed signiﬁcantly lower
ability to calcify the matrix over 2 weeks in culture. (C) Difference in the levels of
CCN3 mRNA between the two populations at conﬂuence as evaluated by real-time
PCR. Data were standardized against 18s rRNA transcript levels. ⁄P = 0.001,
⁄⁄P = 0.01 as indicated by the brackets.
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shown in Fig. 1D, a distinct signal was observed with the same
anti-CCN3 antibody used for the immunoﬂuorescence analysis.
Western blotting analysis of the extract with an antibody against
actin revealed a strong signal, indicating signiﬁcant involvement
of cell lysate as well as extracellular matrix therein.
3.2. Effect of exogenous CCN3 on proteoglycan production by
epiphyseal chondrocytes
Since CCN3 was present in the epiphyseal poles of developing
femurs, we subsequently evaluated its biological effect on the cells
therein. It was previously shown that the differentiation of mouse
costal chondrocytes was repressed by rCCN3 [11]. However, and
surprisingly, rCCN3 promoted proteoglycan synthesis by the
epiphyseal chondrocytes. When estimated by [35S] sulfate incorpo-
ration, enhanced proteoglycan synthesis was observed as short as
22 h after the addition of rCCN3 at 2 nM (Fig. 2A); whereas the
lower concentration (0.5 nM) had no signiﬁcant effect (data not
shown). These results were consistent with our recent preliminary
report [17]. To further conﬁrm this CCN3 activity, we evaluated the
effect of long-term application of rCCN3 by performing a matrixmaturation assay. Consequently, the proteoglycan synthesis
promoted by rCCN3 actually increased the proteoglycan content
accumulated during the course of 2 weeks, as revealed by alcian
blue staining (Fig. 2B). It is worth noting that even this lower con-
centration of rCCN3 yielded a statistically signiﬁcant increase in
proteoglycan accumulation over the 2-week period.
3.3. Effect of exogenous CCN3 on the proliferation of epiphyseal
chondrocytes
Using the epiphyseal chondrocytes, we then evaluated the ef-
fect of exogenous rCCN3 on their proliferation. As expected from
our previous ﬁndings [11,17], DNA synthesis, as estimated by
[3H] thymidine incorporation, was decreased by 2 nM rCCN3
(Fig. 3A). The decreased DNA synthesis was accompanied by
reduced mitochondrial metabolic activity, as demonstrated by
the WST-1 assay (Fig. 3B). The observed down-regulation of DNA
synthesis and mitochondrial metabolic activity are strongly indic-
ative that rCCN3 inhibited epiphyseal chondrocyte proliferation,
3038 D. Janune et al. / FEBS Letters 585 (2011) 3033–3040which is consistent with a number of previous ﬁndings on various
types of cells [11,18–20].
3.4. Novel effects of exogenous CCN3 on the chondrocytic
differentiation
For further functional characterization of CCN3, we isolated
costal, as well as epiphyseal chondrocytes from developing rats.
Phenotype assessment showed that epiphyseal chondrocytes were
close to articular chondrocytes. We found that the number of cells
producing tenascin-C, which was a typical marker of articular
chondrocytes, was strikingly higher in the epiphyseal chondro-
cytes (Fig. 4A). In contrast, costal chondrocytes were mostly
composed of type X collagen-positive cells, which are committed
to hypertrophic differentiation (data not shown). The higher
matrix calciﬁcation level presented by the costal chondrocytes
than by the epiphyseal ones, as shown by the matrix calciﬁcation
assay (Fig. 4B), corroborates these phenotypical differences. Impor-
tantly, the expression level of the CCN3 gene was shown to be
remarkably higher in epiphyseal chondrocytes, indicating a spe-
ciﬁc role of CCN3 therein (Fig. 4C).
Using the cells from epiphysis, we initially evaluated the effect
of rCCN3 on the phenotype representing articular or growth plate
chondrocytes. The gene expression of the core protein of aggrecan,
which is the most abundant proteoglycan in cartilage, was up-
regulated at 48 h after the addition of rCCN3 (Fig. 5A). Gene expres-
sion of tenascin-C, a marker protein present in articular cartilage
matrix, also displayed remarkable up-regulation in those cells by
rCCN3 (Fig. 5B). On the contrary, type X collagen gene expression0
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Fig. 5. Quantiﬁcation of the transcripts of chondrocytic marker genes by real-time RT-PC
of aggrecan core protein transcript in epiphyseal chondrocytes. (B) Induction of the
chondrocytes. (C) Repression of the type X collagen transcript, representing chondrocytic
the tenascin-C transcript in costal chondrocytes. Data were standardized against 18s rRN
and presented as relative values against those with GST. ⁄P = 0.002, ⁄⁄P = 0.02, #P = 0.07,representing differentiation towards calciﬁcation displayedmarked
down-regulation upon 48 h of rCCN3 treatment (Fig. 5C). Interest-
ingly, similar effect on tenascin-C was observed, albeit at a margin-
ally signiﬁcant level (Fig. 5D), even in costal chondrocytes that
would never become articular chondrocytes. These results indicate
that CCN3 can direct developing chondrocytes to differentiate to-
wards non-calcifying articular chondrocytes.
3.5. Effect of RNAi-mediated silencing of the CCN3 gene on a
chondrocyte progenitor, ATDC5
In order to further conﬁrm the effect of CCN3, which directed
the chondrocytic differentiation towards articular chondrocytes,
an RNAi-mediated gene silencing strategy was applied to a murine
chondrogenic cell line, ATDC5. After the infection with a retroviral
vector designed to express a short hairpin siRNA precursor against
murine CCN3 mRNA, early chondrocytic differentiation was
induced by the addition of ITS. In these experiments, the degree
of silencing was not striking (69.1 ± 26.0% of the control at the
mRNA level). However, even such a modest repression of the
CCN3 gene expression resulted in signiﬁcant changes in the gene
expression of tenascin-C and type X collagen. Namely, the mRNA
level of tenascin-C was repressed, whereas that of type X collagen
was increased (Fig. 6). The level of aggrecan mRNA was not signif-
icantly affected by the shRNA, probably because of the limited de-
gree of gene silencing. These results are consistent with the data
with rCCN3 and further indicate the contribution of CCN3 in direct-
ing immature chondrocytes towards the pathway of differentiation
to articular chondrocytes.GST GST-NOV
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Fig. 6. Effect of the CCN3 gene silencing by an shRNA on chondrocytic marker gene
expression. (A) Effect on aggrecan mRNA level. (B) Repression of the tenascin-C
mRNA level. (C) Induction of type X collagen mRNA. Data were standardized against
18s rRNA transcript levels. ⁄P = 0.04, ⁄⁄P = 0.03, as indicated by the brackets.
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Immunohistochemical analysis conﬁrmed that, in developing
stage, epiphyseal cartilage strongly produced CCN3. The presence
of CCN3 protein in developing epiphyseal cartilage denotes critical
roles in articular cartilage development, which is also suggested by
the phenotype of a particular type of Ccn3 mutant mice [21]. First,
the proliferation-inhibiting effect exerted by CCN3 bestowed these
cells with low mitotic activity, one of the characteristics of articu-
lar chondrocytes. This proliferation inhibitory effect was already
expected, because CCN3 is widely known as a repressor of cell pro-
liferation [18–20,22]. In this context, it should be noted that
rCCN3-treated cells showed more polygonal morphology, whereas
CCN3-silencing appeared to yield spindle-shaped cells proliferat-
ing faster (data not shown). Second, a surprising and unexpectedresult found presently was the enhanced matrix production seen
in epiphyseal chondrocytes treated with CCN3. This effect was sol-
idly conﬁrmed by the up-regulation of aggrecan core protein gene
transcript and increase in [35S] sulfate incorporation as well as in
proteoglycan accumulation in culture. Kawaki et al. had earlier
shown that CCN3 rather reduced matrix production in cultures of
mouse costal chondrocytes [11]. It must be emphasized; however,
that they performed their study by using costal chondrocytes com-
mitted to endochondral ossiﬁcation, and thus the apparent dis-
crepancy between the data presented here and theirs indeed
represents phenotypical differences between costal and epiphyseal
chondrocytes. Other apparent contradiction with the ﬁndings in
other previous studies with costal chondrocytes can be also
ascribed to this issue [23]. Such a difference itself can be an expla-
nation as to why different effects were revealed in each work, since
the functionality of CCN family members is highly dependent on
the cellular background and microenvironment. In consequence,
abundant extracellular matrix components are essential for con-
structing articular cartilage, whereas matrix degradation is the
dominant event at the ﬁnal stage of endochondral ossiﬁcation,
which should be accompanied by a decrease in matrix production.
Indeed, CCN3 plays positive and negative roles in both articular
cartilage formation and endochondral ossiﬁcation, respectively,
for harmonized tissue development.
In addition to the proteoglycan synthesis, CCN3 was found to
remarkably increase tenascin-C gene expression in epiphyseal
chondrocytes, which represent the promotion of differentiation to-
ward articular chondrocytes. Interestingly, similar effect was ob-
served also on costal chondrocytes undergoing endochondral
ossiﬁcation, albeit at a reduced level. Another ﬁnding that adds
weight to our proposal was the repression of collagen type X gene
expression after CCN3 treatment, indicating that CCN3 functions to
direct chondrocytes away from the endochondral pathway [11].
This hypothesis was ﬁrmly supported by a different experimental
strategy with a chondrocyte progenitor cell line, ATDC5. These re-
sults together suggest a novel effect of CCN3 that may direct epiph-
yseal chondrocyte towards articular cartilage construction.
Unlike CCN2, which has been proven to promote matrix pro-
duction and proliferation indistinctly on both articular and
growth-plate chondrocytes [9], CCN3 appears to be a promoter
of characteristics speciﬁc to articular chondrocytes in detriment
of those speciﬁc to transient chondrocytes. Nevertheless, CCN3
and CCN2 would collaborate together in articular cartilage, be-
cause, although CCN2 promotes calciﬁcation in growth-plate
chondrocytes, such action is not seen in articular chondrocytes
[9]. In light of the new data presented here, we propose that
CCN3 is the molecule behind the non-calcifying phenotype of
articular chondrocytes even in the presence of CCN2. It should
be also noted that, unlike previously reported for costal chondro-
cytes [11], exogenous CCN3 did not induce Ccn2 down-regulation
in epiphyseal chondrocytes (data not shown).
Considering these ﬁndings collectively, we also propose that the
down-regulation of CCN3 in articular cartilage may be involved in
the genesis of osteoarthritis, which is indeed suggested by the data
shown in Fig. 6. External factors, such as mechanical overload to
the articular cartilage, could turn CCN3 off, inducing chondrocytes
to enter the endochondral ossiﬁcation pathway to form osteo-
phytes [24]. Further investigation on CCN3 in relation to the path-
ogenesis and treatment of osteoarthritis is currently in progress.
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